The evolving landscape of RAS-targeted therapies

Sandra Misale

doi:10.1038/s43018-025-01077-z

The evolving landscape of RAS-targeted therapies

Sandra Misale

School of Medicine

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The initial discovery of an inhibitor of KRAS G12C revolutionized the KRAS field. Since then, more-potent G12C-specific inhibitors, newer allele-specific inhibitors and combinations based on KRAS targeting have advanced through clinical trials, which has led to approval by the US Food and Drug Administration of the first KRAS–EGFR inhibition combinations.

Original language	English (US)
Pages (from-to)	1913-1915
Number of pages	3
Journal	Nature Cancer
Volume	6
Issue number	12
DOIs	https://doi.org/10.1038/s43018-025-01077-z
State	Published - Dec 2025

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1038/s43018-025-01077-z

Cite this

@article{c5d7f29884594f8ea98cc734df6464dd,

title = "The evolving landscape of RAS-targeted therapies",

abstract = "The initial discovery of an inhibitor of KRAS G12C revolutionized the KRAS field. Since then, more-potent G12C-specific inhibitors, newer allele-specific inhibitors and combinations based on KRAS targeting have advanced through clinical trials, which has led to approval by the US Food and Drug Administration of the first KRAS{\textendash}EGFR inhibition combinations.",

author = "Sandra Misale",

note = "Publisher Copyright: {\textcopyright} Springer Nature America, Inc 2025.",

year = "2025",

month = dec,

doi = "10.1038/s43018-025-01077-z",

language = "English (US)",

volume = "6",

pages = "1913--1915",

journal = "Nature Cancer",

issn = "2662-1347",

publisher = "Nature Research",

number = "12",

}

TY - JOUR

T1 - The evolving landscape of RAS-targeted therapies

AU - Misale, Sandra

N1 - Publisher Copyright: © Springer Nature America, Inc 2025.

PY - 2025/12

Y1 - 2025/12

N2 - The initial discovery of an inhibitor of KRAS G12C revolutionized the KRAS field. Since then, more-potent G12C-specific inhibitors, newer allele-specific inhibitors and combinations based on KRAS targeting have advanced through clinical trials, which has led to approval by the US Food and Drug Administration of the first KRAS–EGFR inhibition combinations.

AB - The initial discovery of an inhibitor of KRAS G12C revolutionized the KRAS field. Since then, more-potent G12C-specific inhibitors, newer allele-specific inhibitors and combinations based on KRAS targeting have advanced through clinical trials, which has led to approval by the US Food and Drug Administration of the first KRAS–EGFR inhibition combinations.

UR - https://www.scopus.com/pages/publications/105024762949

UR - https://www.scopus.com/pages/publications/105024762949#tab=citedBy

U2 - 10.1038/s43018-025-01077-z

DO - 10.1038/s43018-025-01077-z

M3 - Comment/debate

C2 - 41372477

AN - SCOPUS:105024762949

SN - 2662-1347

VL - 6

SP - 1913

EP - 1915

JO - Nature Cancer

JF - Nature Cancer

IS - 12

ER -

The evolving landscape of RAS-targeted therapies

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this